EVALUATION OF PSYCHOTROPIC DRUGS
|
|
- Melina Shepherd
- 5 years ago
- Views:
Transcription
1 Br. J. clin. Pharmac. (1976), Supplement, THE SIGNIFICANCE OF DRUG INTERACTIONS IN THE EVALUATION OF PSYCHOTROPIC DRUGS R.A. BRAITHWAITE National Poisons Information Centre and Poisons Unit, Guy's Hospital, London SE1 In recent years the subject of drug interactions has attracted much attention and numerous lists of possible adverse interactions have been widely publicized. However, a large number of interactions have been postulated purely on the basis of animal experiments, in vitro microsomal studies and single clinical cases. Thus, it has become difficult for the practising clinician to distinguish clearly between those interactions which are important and supported by good clinical evidence, and those which are of doubtful or even mythical occurrence. It is impossible to validate suspected drug interactions on the basis of single-dose studies in two or three volunteer subjects. In order to substantiate fully an interaction between two drugs, studies should be carried out under experimental conditions which are as close to the therapeutic situation as possible. Usually, this is at 'steady-state' and where the drugs in question have been administered over a period of several weeks, often throughout the illness. Drug interactions, particularly in the field of psychiatric medicine, should be recognized as being one of several factors which can modify clinical response. As their overall importance has yet to be fully established, one cannot be complacent about the situation, since the practice of polypharmacy is probably at its zenith in psychiatric medicine. When two or more drugs are prescribed together, the resultant pharmacological effect may be the same, greater or less than that predicted from the pharmacological actions of the individual drugs concerned. Two concurrently administered drugs may interact for one or several reasons, but some of the principal mechanisms involved in precipitating a drug interaction are shown in Table 1. Some interactions concerning psychotropic preparations are clinically important and fortunately are now well recognized by clinicians. These are the interaction between monoamine oxidase (MAO) inhibitor drugs and sympathomimetic amines (Sjoqvist, 1965; Granville-Grossman, 1971), and that between guanidine hypotensive agents and tricyclic antidepressant drugs (Skinner, Coull & Johnson, 1969; Mitchell, Arias & Oates, 1967; Meyer, McAllister & Goldberg, 1970; Mitchell et al., 1970). Concerning the reported adverse reaction between MAO inhibitors and tricyclic antidepressants, the subject is still very much open to debate (Stockley, 1974), with much clinical evidence in support of the therapeutic benefits of such combinations, principally that from the work of Sargant (1971). Problems associated with interactions or interference at the site of drug absorption have come much more into focus in recent years. In particular, the low bioavailability of oral chlorpromazine preparations which results from metabolism of the drug as it passes through the intestinal wall has obviously had an influence on the dosage form of phenothiazine preparations (Curry, D'Mello & Mould, 1971; Hollister & Curry, 1971). It is now well known that many hypnotic and sedative drugs, particularly the barbiturates, are potent inducers of hepatic microsomal enzymes in man and can lead to an enhanced rate of drug metabolism (Conney, 1967; Prescott, 1971; Breckenridge & Orme, 1971; McDonald et al., 1969; Stephenson et al., 1972). The influence of concurrent barbiturate administration on steady-state tricyclic antidepressant plasma concentrations has been recently documented by Swedish workers (Hammer, Idestrom & Sjoqvist, 1967; Alexanderson, Prince- Evans & Sjoqvist, 1969). In a study of our own, shortly to be published, we have found that steadystate plasma nortriptyline concentrations in maximally induced epileptic patients are less by about 60% than those found in other non-induced, depressed patients Table 1 Principle mechanisms of drug interactions 1. Interference with drug absorption 2. Plasma-protein binding (a) displacement (b) increased binding 3. Drug distribution and tissue uptake 4. Competition or interference at receptor site(s) 5. Hepatic drug metabolism (a) induction (b) inhibition 6. Renal drug excretion (a) increased (b) decreased 7. Miscellaneous (a) inhibition of monoamine oxidase
2 30 R.A. BRAITHWAITE Nortriptyline (100 mg/day) Nitrazepam (10 mg/day) Chlordiazepoxide (40 mg/day) Chlordiazepoxide (40 mg/day) Diazepam (20 mg/day) 0)~~~~~~~~~~~~~~~~~7 C i, oc 1o50 I I I Il I I II II Diazepam (40 mg/day) IE U,1 en Time (days) Figure 1 Plasma nortriptyline concentrations in a patient during chronic antidepressant medication with nortriptyline, also concurrent medication with nitrazepam, diazepam and chlordiazepoxide. receiving equivalent doses of nortriptyline (Braithwaite & Richens, 1974). Concerning the inhibition of drug metabolism, the situation is still unclear and very few clinical studies concerning psychotropic drugs have been published. Moody and his associates reported a large increase in one patient's plasma imipramine and desipramine levels when chlorpromazine was combined with the imipramine medication (Moody, Tait & Todrick, 1967). More recently Gram and Fredericson-Overo (1972) demonstrated that the drugs perphenazine, haloperidol and chlorpromazine were able to inhibit significantly the metabolism of imipramine and nortriptyline. However, this latter study was carried out by administering single doses of "4C-labelled antidepressant, before, during and after brief treatment with the various neuroleptics; therefore, the clinical significance of this study is uncertain. The central stimulant drug methylphenidate (Ritalin) has been shown to be a potent inhibitor of imipramine metabolism, causing dramatic increases in plasma imipramine and desipramine concentrations in patients (Wharton et al., 1971). However, the effect of methylphenidate administration on plasma anticonvulsant levels is controversial. In one study methylphenidate inhibited the metabolism of anticonvulsant levels and produced toxicity in one patient (Garrettson, Perel & Dayton, 1969). More recently Kupferberg and associates (Kupferberg, Jeffery & Hunninghake, 1972) reported that methylphenidate administration to 11 epileptic patients for a 6-week period, did not alter plasma anticonvulsant concentrations from control values. In contrast to the above compounds, the benzodiazepine group of drugs seem free of any clinically significant potential with regard to both the inhibition or induction of hepatic drug metabolism (Orme, Breckenridge & Brooks, 1972; Silverman & Braithwaite, 1973). That the benzodiazepines do not have any significant influence upon steady-state plasma concentrations of tricyclic antidepressants may be seen in Figures 1 and 2. Despite many such studies, we are still no nearer an assessment of the overall significance of drug interactions in clinical psychiatric practice. In the treatment of depression in general practice and in hospital outpatient clinics, poly-pharmacy seems to be the rule rather than the exception. In a random survey of 13 patients who were ostensibly receiving antidepressant medication with nortriptyline, most were also receiving concurrent medication with various other psychotropic preparations (Table 2), of whom six were receiving various 'enzyme inducing' hypnotics. The plasma nortriptyline levels recorded in this same group of patients ranged from 20 to 246 ng/ml, a 12-fold variation (Table 2). Thus, at first sight, drug interactions may have produced some of the variation in plasma nortriptyline concentrations observed in this group of patients. Several recent studies have demonstrated a relationship between plasma concentrations of a number of tricyclic antidepressant drugs and clinical response. Moreover, therapeutic failure in a number of patients may be due to either very low or even too high plasma antidepressant concentrations (Walter, 1971; Asberg et al., 1971; Braithwaite et al., 1972; Kragh-Sorensen, Asberg & Eggert-Hansen, 1973). These studies in the main have been carefully conducted, using selected patients, quantitative rating
3 SIGNIFICANCE OF DRUG INTERACTIONS 31 Amitriptyline (80 mg/day) Oxazepam 45 mg/day i 60 G) (D Time (days) Figure 2 Plasma amitriptyline (U) and nortriptyline (0) concentrations in a patient during chronic antidepressant medication with amitriptyline, also concurrent medication with oxazepam. scales and the repeated estimation of plasma antidepressant concentrations. The concurrent administration of other psychotropic preparations was reduced to a minimum. In marked contrast to the above studies, a multi-centre trial was carried out to investigate the relationship between plasma nortriptyline concentrations and clinical response in a large group of depressed outpatients treated with various doses of nortriptyline (Collaborative Study, 1974). In this study no relationship whatsoever was observed between plasma nortriptyline concentrations and either a satisfactory or unsatisfactory clinical response (Figure 3). However, of the 45 patients investigated, two-thirds were also receiving concurrent medication with other psychotropic compounds, namely: 19 patients were receiving benzodiazepines, six receiving phenothiazines, three receiving lithium and five receiving various hypnotic or sedative drugs. The problem of the interpretation of drug-plasma concentration data in such studies is obvious. This may be illustrated by the cases of two patients included in the study. The first patient was reported as having a satisfactory clinical response to nortriptyline and had a plasma level of 161 ng/ml; however, this patient was also receiving chlorpromazine, chlordiazepoxide and nitrazepam. The second patient was reported as having an unsatisfactory clinical response and had a plasma nortriptyline level of only 20 ng/ml; this patient was also receiving glutethimide, nitrazepam and phenobarbitone. The last had not been prescribed and was only detected by analysis of the patient's urine. Table 2 Plasma nortriptyline levels in randomly selected patients receiving nortriptyline Patient Daily dose of Plasmanortriptyline No. Sex nortriptyline level Concomitant medication (mg) (ng/ml) 1 M F Promazine, dichloralphenazone 3 F F Promazine, dichloralphenazone 5 F Amylobarbitone, quinalbarbitone Promazine 7 F Nitrazepam Chlorpromazine 9 F Diazepam 10 F F Amylobarbitone 12 F Amylobarbitone 13 F (dose unknown) 100 Diazepam, phenytoin, promazine methaqualone, diphenhydramine
4 32 R.A. BRAITHWAITE :...:..:., '.,..P,latma,rYotW 1 leve (ng/ml) ' ' 1,''*,:::' -, 0. r.~ 10,. 2;.,5-0.~ ~ AGO...*. atactory Us patients. Figure 3 The relationship between plasma nortriptyline concentrations and 'satisfactory' and unsatisfactory clinical response in a group of 45 depressed outpatients treated with nortriptyline. Each box represents one patient. (Figure taken from Collaborative Study, 1974.) Thus, it can be seen that in the clinical assessment of a particular antidepressant medication, the concurrent administration of other psychotropic preparations is an obvious complicating factor, but the ) 300 co cx E 200 co 100 Patients Figure 4 Mean steady-state plasma nortriptyline levels in patients receiving nortriptyline ( mg/ day). (R.A. Braithwaite, unpublished material.) overall clinical significance of these 'interactions' in the practical treatment of such a diverse and complex illness as depression is difficult, perhaps impossible to assess. But other equally important factors influencing clinical response and possible drug interactions have also to be considered. First, there are large individual differences in the rates of tricyclic antidepressant metabolism which are largely genetically determined. Patients receiving similar 'therapeutic' doses of drug may have very different steady-state plasma concentrations (Figures 4 and 5). Second, a large proportion of patients may not take their medication as prescribed. Willcox, Gillan & Hare (1965) reported that 40% of a group of psychiatric outpatients being treated for depression with imipramine were not taking their medication as prescribed and, more recently, a study by Johnson (1973) of depressed patients treated in general practice, showed that of the patients given 'therapeutic' doses of antidepressant, about 50% had stopped taking their drugs 3 weeks after they were first prescribed. Finally, those drugs which are potent inducers of hepatic microsomal enzymes may give rise in the long term to complications due to enhanced rates of endogenous vitamin and steroid metabolism (Greenwood, Prunty & Silver, 1973). In conclusion, it
5 SIGNIFICANCE OF DRUG INTERACTIONS CD 100 E CD Patients Figure 5 Mean steady-state plasma amitriptyline (-) and nortriptyline (0) levels in patients receiving amitriptyline ( mg/day) (R.A. Braithwaite, unpublished material.) seems desirable that those patients who require chronic psychotropic medication should receive those preparations which are not potent inducers of metabolism. Further, many of the complications of those interactions influencing rates of drug metabolism could in fact be easily avoided by the judicious adjustment of drug dosages and by monitoring drug plasma concentrations during therapy. References ALEXANDERSON, B., PRICE-EVANS, D.A. & SJOQVIST, F. (1969). Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy. Br. Med. J., 4, ASBERG, M. et al. (1971). Relationship between plasma level and therapeutic effect of nortriptyline, Br. Med. J., 3, BRAITHWAITE, R.A. et al. (1972). Plasma concentration of amitriptyline and clinical response, Lancet i, BRAITHWAITE, R.A. & RICHENS, A. (1974). To be published. BRECKENRIDGE, A. & ORME, M. (1971). Clinical implications of enzyme induction. Ann. N.Y. A cad. Sci., 179, COLLABORATIVE STUDY (1974). Post. Grad. Med. J. To be published. CONNEY, A.H. (1967). Pharmacological implications of microsomal enzyme induction. Pharmac. Rev., 19, CURRY, S.H., D'MELLO, A. & MOULD, G.P. (1971). Destruction of chlorpromazine during absorption in the rat in vivo and in vitro. Br. J. Pharmac., 42, GARRETTSON, L.K., PEREL, J.M. & DAYTON, P.G. (1969). Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate. J. Amer. med. Assoc., 207, GRAM, L.F. & FREDRICSON-OVERO, K. (1972). Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br. Med. J., 1, GRANVILLE-GROSSMAN, K. (1971). In: Recent Advances in Clinical Psychiatry, p.43. London: J. & A. Churchill. GREENWOOD, R.H., PRUNTY, F.T.G. & SILVER, J. (1973). Osteomalacia after prolonged glutethimide administration. Br. Med. J., 1, HAMMER, W., IDESTROM, C.M. & SJOQVIST, F. (1967). Chemical control of antidepressant drug therapy. In Garattini, S. and Dukes, M.N.G. (eds) Proc. 1st Int. symp. on antidepressant drugs, Milan Excerpta Medica Int. Congr. Ser., 122, HOLLISTER, L.E. & CURRY, S.H. (1971). Urinary excretion of chlorpromazine metabolites following single doses and in steady state conditions. Res. Comm. Chem. Path. Pharmac., 2, JOHNSON, D.A.W. (1973). Treatment of depression in general practice. Br. Med. J., 2, KRAGH-SORENSEN, P., ASBERG, M. & EGGERT-HANSEN, C. (1973). Plasma nortriptyline levels in endogenous depression. Lancet, i, KUPFERBERG, H.J., JEFFERY, W. & HUNNINGHAKE, D.B. (1972). Effect of methyl phenidate on plasma anticonvulsant levels. Clin. Pharmac. Ther., 13, McDONALD, M.G. et al. (1969). The effects of phenobarbital, chloral betaine, and glutethimide administration on warfarin plasma levels and hypoprothrombinemic responses in man. Clin. pharmac. Ther., 10, MEYER, J.F., McALLISTER, C.K. & GOLDBERG, L.I. (1970). Insidious and prolonged antagonism of guanethidine by amitriptyline. J. Amer. med. Assoc., 213,
6 34 R.A. BRAITHWAITE MITCHELL, J.R. et al.. (1970). Guanethidine and related agents III: antagonism by drugs which inhibit the norepinephrine pump in man. J. Clin. Invest., 49, MITCHELL, J.R., ARIAS, L. & OATES, J.A. (1967). Antagonism of the antihypertensive action of guanethidine sulphate by desipramine hydrochloride. J. Am. med. Ass., 202, MOODY, J.P., TAIT, A. C. & TODRICK, A. (1967). Plasma levels of imipramine and desmethylimipramine during therapy. Br. J. Psychiat., 113, ORME, M., BRECKENRIDGE, A. & BROOKS, R.V. (1972). Interactions of benzodiazepines with warfarin. Br. Med. J.,3, PRESCOTT, L.F. (1971). Drug metabolism and therapeutics. Scott. med. J., 16, SARGANT, W. (1971). Safety of combined anti-depressant drugs. Br. med. J., 1, SILVERMAN, G. & BRAITHWAITE, R.A. (1973). Benzodiazepines and tricyclic antidepressant plasma levels. Br. Med. J., 3, SJOQVIST, F. (1965). Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc. roy. Soc. Med., 58, SKINNER, C., COULL, D.C. & JOHNSON, A.W. (1969). Antagonism of the hypotensive action of bethanidine and debrisoquine by tricyclic antidepressants. Lancet, ii, STEPHENSON, I.H. et al. (1972). Changes in human drug metabolism after long-term exposure to hypnotics. Br. Med. J., 4, STOCKLEY, I. (1974). In Drug Interactions, p. 15. London: The Pharmaceutical Society Press. WALTER, C.J.S. (1971). Drug plasma levels and clinical effect. Proc. roy. Soc. Med., 64, WILLCOX, D.R.C., GILLAN, R. & HARE, E.H. (1965). Do psychiatric outpatients take their drugs? Br. Med. J., 2, WHARTON, R.N. et al. (1971). A potential clinical use for methylphenidate with tricyclic antidepressants. Amer. J. Psychiat. 127,
The drug dilemma-benefits and hazards Drug interactions and lethal drug combinations
J. clin. Path., 28, Suppl. (Roy. Coll. Path.), 9, 94-98 The drug dilemma-benefits and hazards Drug interactions and lethal drug combinations ALAN RICHENS From the Department of Clinical Pharmacology, St
More informationtests of haematological, renal, hepatic and metabolic 'cheese reaction' with monoamine oxidase inhibitors
Br. J. clin. Pharmac. (1976), Supplement, 35-40 SCREENING PROCEDURES IN VOLUNTEERS AND PATIENTS P.J. TYRER University of Southampton, Southampton General Hospital, Tremona Road, Southampton The chief object
More informationTranquilizers & Sedative-Hypnotics
Tranquilizers & Sedative-Hypnotics 1 Tranquilizer or anxiolytic: Drugs used therapeutically to treat agitation or anxiety Sedative-Hypnotic: drugs used to sedate and aid in sleep Original sedatives (before
More informationFigure 1 The structure of antipyrine (1 -phenyl-2,3- groups, have looked at the factors which influence. antipyrine metabolism in man.
Br. J. clin. Pharmac. (1977),, 261-265 THE FIRST LILLY PRIZE LECTURE UNIVERSITY OF DUNDEE, JULY 1976 FACTORS INFLUENCING ANTIPYRINE ELIMINATION I.H. STEVENSON Department of Pharmacology and Therapeutics,
More informationCLINICAL TRIALS OF FLUVOXAMINE VS CHLORIMIPRAMINE WITH SINGLE AND THREE TIMES DAILY DOSING
Br. J. cin. Pharmac. (1983), 15, 427S-431S CLINICAL TRIALS OF FLUVOXAMINE VS CHLORIMIPRAMINE WITH SINGLE AND THREE TIMES DAILY DOSING J.E. DE WILDE, C. MERTENS & J.S. WAKELIN' Psychiatrisch Ziekenhuis
More informationInfluence of allopurinol on drug metabolism in man
Br. J. Pharmac. (1973), 48, 693-698. Influence of allopurinol on drug metabolism in man M. D. RAWLINS* AND S. E. SMITH Departments of Medicine and Pharmacology, St. Thomas's Hospital Medical School, London
More informationSmoking Cessation Pharmacotherapy Guidelines
Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence
More informationSMOKING AND DRUG INTERACTIONS
Medicines Information Centre Pharmacy Department UK Medicines Information SMOKING AND DRUG INTERACTIONS Introduction Smoking rates are significantly higher among people with mental health problems. It
More informationEffective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)
1 Policy #: 803 (PLH-803-02) Effective Date: NA Reviewed Date: 4/11/2008 Subject: URINE DRUG SCREENS Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) Approved by: Laboratory
More informationAnxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anxiolytic, Sedative and Hypnotic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anxiolytics: reduce anxiety Sedatives: decrease activity, calming
More informationOld drugs in modern psychogeriatry
Old drugs in modern psychogeriatry Some historical events in psychopharmacology Chemotherapy of depression Commonly used hypnotics and anti-anxiety ( minor tranquilizers ) Anti-psychotics ( major tranquilizers
More informationOrientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology
Orientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology Objective: To discuss basic principles of psychopharmacology in children and adolescents. Pharmacokinetics:
More informationActive ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg
Name Primperan 10 mg / 2 ml Metoclopramide hydrochloride anhydrous Solution for I.M. or I.V. injection (Ampoules) Composition Each 2 ml ampoule contains: Active ingredients: Metoclopramide Hydrochloride.
More informationPharmacology in the Elderly
Pharmacology in the Elderly James Hardy Geriatrician, Royal North Shore Hospital A recent consultation Aspirin Clopidogrel Warfarin Coloxyl with senna Clearlax Methotrexate Paracetamol Pantoprazole Cholecalciferol
More informationPRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist
PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines
More informationThe effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics
Br. J. clin. Pharmac. (1984), 18, 393-400 The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics T. K. DANESHMEND* & C. J. C. ROBERTS University Department of Medicine, Bristol
More informationMetabolism. Objectives. Metabolism. 26 July Chapter 28 1
Metabolism bjectives Describe various processes by which drugs are metabolized Describe induction and inhibition of metabolism Use the venous equilibration model to describe hepatic clearance and the effect
More informationEFFECTS OF MICROSOMAL ENZYME INDUCTION ON PARACETAMOL METABOLISM IN MAN
Br. J. clin. Pharmac. (1981),12,149-153 EFFECTS OF MICROSOMAL ENZYME INDUCTION ON PARACETAMOL METABOLISM IN MAN L.F. PRESCOT, J.A.J.H. CRITCHLEY, M. BALALI-MOOD & B. PENTLAND University Departments of
More informationTHE PHARMACOKINETICS OF NORTRIPTYLINE IN PATIENTS WITH CHRONIC RENAL FAILURE
Br J clin Pharmac (1981), 12, 39-45 THE PHARMACOKINETICS OF NORTRIPTYLINE IN PATIENTS WITH CHRONIC RENAL FAILURE S DAWLING, K LYNN,'* R ROSSER2 & R BRAITHWAITE** Poisons Unit, Guy's Hospital and Departments
More informationACTIONS OF BRETYLIUM AND GUANETHIDINE ON THE UPTAKE AND RELEASE OF [3H]-NORADRENALINE
Brit. J. Pharmacol. (1962), 18, 161-166. ACTIONS OF BRETYLIUM AND GUANETHIDINE ON THE UPTAKE AND RELEASE OF [3H]-NORADRENALINE BY G. HERTTING,* J. AXELROD AND R. W. PATRICK From the Laboratory of Clinical
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationNew Test Announcements
27027 Tourney Road Valencia, CA 91355 800 421 7110 www.specialtylabs.com New Test Announcements Dear Colleague: We are pleased to announce many new test offerings this month. January 25, 2007 In oncology,
More informationA substance that reduces pain and may or may not have psychoactive properties.
GLOSSARY OF TERMS AMPHETAMINE-TYPE STIMULANTS (ATS) A group of substances, mostly synthetic, with closely related chemical structure which have, to varying degrees, a stimulating effect on the central
More informationSingle dose pharmacokinetic study of clobazam in normal
Br. J. clin. Pharmac. (1984), 18, 873-877 Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients S. JAWAD & A.. RICHS Department of Pharmacology and Therapeutics, Welsh
More informationGeriatric Pharmacology. Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center
Geriatric Pharmacology Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center Silver Tsunami 2010: 40 million (13%) 2030: 72 million (20%) Baby Boomers (1946-1964)
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationApplication for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation
Application for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation Below is the form you need to fill out. NAME Dianne Vicary Health Hawke s Bay DATE JUNE 2012 TITLE OF ACTIVITY
More informationAntidepressants and Sedatives. David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School
Antidepressants and Sedatives David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School Depression A frequent problem, affecting up to 5% of the population Common presentations
More informationBlood pressure and pulse should be recorded on a centile chart at each dose adjustment and then at least every 6 months
Checklist 1: checklist before prescribing Amfexa 5mg, 10mg and 20mg Tablets It is recommended that this checklist be used in conjunction with the SmPCs for Amfexa Tablets (which can be accessed at http://www.medicines.org.uk/emc/search
More informationPHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS
PHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS Yogesh Dwivedi, Ph.D. Assistant Professor of Psychiatry and Pharmacology Psychiatric Institute Department of Psychiatry
More informationa very short half-life, but its main metabolite, which
Br. J. clin. Pharmac. (1979), 8, 3IS-35S BIOAVAILABILITY OF TMAZPAM IN SOFT GLATIN CAPSULS L.M. FUCCLLA Department of Clinical Pharmacology, Carlo rba Research Institute, Milan, Italy 1 Healthy volunteers
More informationNEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.
1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
More informationDrugSmartCup & DrugSmartDip Accuracy Report as produced by Ameditech, Inc.
Accuracy The accuracy of the DrugSmart Drugs of Abuse Tests was evaluated in comparison to commercially available drug screen tests. Sixty (60) negative urine samples collected from presumed non-user volunteers
More informationauditory flutter fusion threshold (A.F.F.T.), is the auditory equivalent of the visual critical
Br. J. Pharmac. Chemother. (1967), 30, 341-348. THE TIME COURSE OF ACTION OF SINGLE DOSES OF DIAZEPAM, CHLORPROMAZINE AND SOME BARBITURATES AS MEASURED BY AUDITORY FLUTTER FUSION AND VISUAL FLICKER FUSION
More informationImpairment of cognitive function associated with hydroxyamylobarbitone accumulation in patients with renal insufficiency
Br. J. Pharmac. (1972), 45, 36-367. Impairment of cognitive function associated with hydroxyamylobarbitone accumulation in patients with renal insufficiency K. BALASUBRAANIA, G. E. AWER, J. E. F POHL.
More informationStudy Guidelines for Quiz #1
Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing
More informationMembership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4
A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Clomicalm 5 mg tablets for dogs Clomicalm 20 mg tablets for dogs Clomicalm 80 mg tablets for dogs 2. QUALITATIVE
More informationCLINICAL PHARMACOKINETIC STUDIES OF PERPHENAZINE
Br. J. clin Pharmac. (197), 3, 91-93 CLINICAL PHARACOKINETIC STUDIES O PERPHENAZINE C. EGGERT HANSEN, T. ROSTED CHRISTENSEN, J. ELLEY, L. BOLVIG HANSEN & P. KRAGH-SRENSEN Departments & R, Glostrup ental
More informationA. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention
DRUG OUTLINE A. Definition B. Epidemiology Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/09/05) C. Classification i. Pharmacokinetic DIs ii. Pharmacodynamic DIs D. Recognition E. Prevention
More informationMETABOLISM. Ali Alhoshani, B.Pharm, Ph.D. Office: 2B 84
METABOLISM Ali Alhoshani, B.Pharm, Ph.D. ahoshani@ksu.edu.sa Office: 2B 84 Metabolism By the end of this lecture, you should: Recognize the importance of biotransformation Know the different sites for
More informationSouth London and the Maudsley NHS Foundation Trust Medicines Formulary
South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1
More informationSUMMARY OF PRODUCT CHARATERISTICS HYPERIUM. I.N.N. : Rilmenidine
SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM I.N.N. : Rilmenidine 1. DENOMINATION HYPERIUM 1 mg, tablets 2. COMPOSITION Rilmenidine (I.N.N.) dihydrogenphosphate.1.544 mg amount equivalent to rilmenidine
More informationAdjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes
Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook
More informationFaculty of dentistry Second year CND Course CNS Drugs Dr. Ali Awadallah
Faculty of dentistry Second year CND Course CNS Drugs Dr. Ali Awadallah 0912320825 Drugs that act upon the central nervous system (CNS) influence the lives of everyone, everyday. Drugs that affect the
More informationCATECHOLAMINE, FREE, RANDOM URINE
Lab Dept: Test Name: Urine/Stool CATECHOLAMINE, FREE, RANDOM URINE General Information Lab Order Codes: Synonyms: CPT Codes: Test Includes: CATCR Catecholamine Fractionation, Free, Random Urine 82384 Catecholamines;
More informationPsychotropic Drugs 0, 4-
0, 4- } -v Psychotropic Drugs NORMAN L. KELTNER, Ed D, RN Associate Professor, Graduate Program, University of Alabama School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama DAVID
More informationP. TURNER M.D., F.R.C.P. (Briant, Reid and Dollery, 1973), is impaired by. treatment with tricyclic antidepressant drugs. Since
Postgraduate Medical Journal (December 1974) 5, 729-733. Some clinical pharmacological studies with indoramin, with observations on its therapeutic usefulness C. DE B. WHITE M.R.C.P. Summary In the treatment
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationTRAPADOL INJECTION FOR I.V./I.M. USE ONLY
TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally
More informationMICROMEDEX Healthcare Series : Document Case 3:09-cv TMB Document Filed 03/24/2010 Page 1 of 105
7/7/2009 MICROMEDEX Healthcare Series : Document Page 1 of 31 Case 3:09-cv-00080-TMB Document 78-23 Filed 03/24/2010 Page 1 of 105 DRUGDEX Evaluations DEXMETHYLPHENIDATE 0.0 Overview 1) Class a) This drug
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationAGE AS A FACTOR AFFECTING LITHIUM THERAPY
Br. J. clin. Pharmac. (1977), 4, 201-205 AGE AS A FACTOR AFFECTING LITHIUM THERAPY D.S. HEWICK & P. NEWBURY Department of Pharmacology & Therapeutics, Ninewells Hospital, Dundee DD1 9SY S. HOPWOOD & G.
More information5-HT 3 -receptor antagonists
5-HT 3 -receptor antagonists 5-HT 3 -receptor antagonists 5-HT 3 -receptor antagonists + Opioids Ondansetron reduces the analgesic efficacy of tramadol and at least double the dose was required in one
More informationClinical Geriatric Psychopharmacology
Clinical Geriatric Psychopharmacology SECOND EDITION CARL SALZMAN, M.D. Director of Psychopharmacology Massachusetts Mental Health Center Associate Professor of Psychiatry Harvard Medical School Boston,
More informationPRODUCT INFORMATION. Active ingredients Chemical structure CAS Registry Number. Paracetamol
PRODUCT INFORMATION PANADOL COLD & FLU MAX + DECONGESTANT HOT LEMON POWDER NAME OF THE MEDICINE Active ingredients Chemical structure CAS Registry Number Paracetamol 103-90-2 Phenylephrine Hydrochloride
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationDrugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD
Drugs, Sleep & Wakefulness Brian Koo Reena Mehra MD MS Kingman Strohl MD Things To Keep In Mind Many drugs effect sleep either causing insomnia or sedation Disruption of sleep and wakefulness may not be
More informationMethods. The scope and operation of the Boston Collaborative Drug Surveillance Program (BCDSP) have been
Br. J. clin. Pharmac. (1978), 5, 47-413 TOXICITY OF NITRAZEPAM IN THE ELDERLY: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM D.J. GREENBLATT & MARCIA D. ALLEN Boston Collaborative Drug
More informationHUMAN PHARMACOLOGY OF ANTIDEPRESSIVES
Br.J. clin. Pharmac. (1977),4, 135S-141S HUMAN PHARMACOLOGY OF ANTIDEPRESSIVES M. LADER Department of Psychiatry, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK I As both the tricyclic
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More information1. NAME OF THE MEDICINAL PRODUCT. Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Oxymetazoline hydrochloride 0.5 mg/ml 1 spray (50 l) contains approximately 25
More informationGerman Journal of Psychiatry 2000; 3
Reprinted from the German Journal of Psychiatry http://www.gjpsy.uni-goettingen.de ISSN 1433-1055 Assuring the Quality of the Utilization of Psychoactive Medication by People with Mental Retardation and
More informationDATA SHEET. Paracetamol (BP) 500 mg and Phenylephrine Hydrochloride (BP) 5 mg
COLDREX PE PHENYLEPHRINE SINUS COLDREX PE PHENYLEPHRINE CONGESTION CLEAR PANADOL SINUS PAIN & CONGESTION RELIEF PANADOL COLD & FLU MAX + DECONGESTANT DATA SHEET Paracetamol (BP) 500 mg and Phenylephrine
More informationBupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL
Bupropion Generic names Available brands Available strengths and formulations Available in generic Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL 75-mg
More informationNORPRAMIN (desipramine hydrochloride USP) is an antidepressant drug of the tricyclic type, and is chemically:
NORPRAMIN (Aventis) (desipramine hydrochloride tablets USP) Prescribing Information as of July 2000 DESCRIPTION NORPRAMIN (desipramine hydrochloride USP) is an antidepressant drug of the tricyclic type,
More informationPharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol
Br. J. clin. Pharmac. (1984), 17, 97S-12S Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol H. SPAHN', W. KIRCH2,. MUTSCHLR',.. OHNHAUS2, N. R. KITFRINGHAM2,
More informationETHNICITY AND PSYCHOTROPIC RESPONSE
Ethnic Differences in Drug Metabolism ETHNICITY AND PSYCHOTROPIC RESPONSE Bridging Cultures: Improving Evaluation & Treatment of Cognitive 8 March 28 Keh-Ming Lin, M.D., M.P.H. Professor Emeritus of Psychiatry,
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationPACKAGE LEAFLET: Information for the user. METFORMINE Film-coated tablets 500 mg, 850 mg or 1000 mg (Metformin hydrochloride)
PACKAGE LEAFLET: Information for the user METFORMINE Film-coated tablets 500 mg, 850 mg or 1000 mg (Metformin hydrochloride) Read this leaflet carefully before you start taking this medicine. - Keep this
More informationTherapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?
Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Prof. Dr. Christoph Hiemke Psychiatrische Klinik und Poliklinik Universität Mainz Psychopharmacotherapy Psychiatric Patient
More informationA NEW TYPE OF DRUG ENHANCEMENT: INCREASED MAXIMUM RESPONSE TO CUMULATIVE NORADREN- ALINE IN THE ISOLATED RAT VAS DEFERENS
Br. J. Pharmac. Chemother. (1968), 33, 171-176. A NEW TYPE OF DRUG ENHANCEMENT: NCREASED MAXMUM RESPONSE TO CUMULATVE NORADREN- ALNE N THE SOLATED RAT VAS DEFERENS BY A. BARNETT, D. D. GREENHOUSE AND R..
More informationNorthSTAR. Pharmacy Manual
NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT YOCON-GLENWOOD Tablets 5 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains 5 mg yohimbine hydrochloride. For a full list of excipients, see section 6.1. 3
More informationPRODUCT INFORMATION. Active ingredients Chemical structure CAS Registry Number. Paracetamol
PRODUCT INFORMATION PANADOL SINUS PAIN & CONGESTION RELIEF CAPLETS PANADOL COLD & FLU PLUS DECONGESTANT CAPLETS NAME OF THE MEDICINE Active ingredients Chemical structure CAS Registry Number Paracetamol
More informationdistinguish between structural isomers (but not necessarily stereoisomers), including, but not
CPT s: 80305 Drug test(s), presumptive, any number of drug classes, any number of devices or procedures (eg, immunoassay); capable of being read by direct optical observation only (eg, dipsticks, cups,
More informationAccess to Essential Medicines for MNS Disorders with the Greatest Burden: Focus on Depression, Psychosis and Epilepsy
Access to Essential Medicines for MNS Disorders with the Greatest Burden: Focus on Depression, Psychosis and Epilepsy Atalay Alem, MD, PhD Department of Psychiatry, School of Medicine, College of Health
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationMINOR TRANQUILIZERS CHAPTER TWO : MINOR TRANQUILIZERS
MINOR TRANQUILIZERS 76. The term 'minor tranquilizers' was introduced into the scientific literature in the 1950s to distinguish the medicines prescribed to reduce anxiety and tension from the major tranquillizers,
More information1. Foods containing tyramine should not be eaten by patients taking: a. Fluvoxamine b. Imipramine c. Maprotiline d. Nefazodone e.
Various Pharmacology Questions 1. Foods containing tyramine should not be eaten by patients taking: a. Fluvoxamine b. Imipramine c. Maprotiline d. Nefazodone e. Tranylcypromine 2. Which is true of Selective
More informationControlled Substance Monitoring and Drugs of Abuse Testing Determination
CPT s: 80305 Drug test(s), presumptive, any number of drug classes, any number of devices or procedures (eg, immunoassay); capable of being read by direct optical observation only (eg, dipsticks, cups,
More informationBenzodiazepines. Benzodiazepines
: History 1950s - Invented by Swiss chemists who identified its sedative effects 1950s 60s - Chlordiazepoxide (Librium) marketed as a safer alternative to barbiturates; along with newer benzodiazepines
More informationRational prescribing in the older adult. Assoc Prof Craig Whitehead
Rational prescribing in the older adult Assoc Prof Craig Whitehead Introduction Physioloical ageing and frailty Medication risks in older adults Drug Burden Anticholinergic and sedative drug burden Cascade
More informationTreating sleep disorders
Treating sleep disorders Sue Wilson Centre for Neuropsychopharmacology Imperial College London sue.wilson@imperial.ac.uk Suggested algorithm for treatment of insomnia Diagnosis of insomnia Associated with
More informationSafe and Effective Use of. Psychotropic Drugs. Introduction. Psychotropic Drugs. Jun NAKAMURA
Psychotropic Drugs Safe and Effective Use of Psychotropic Drugs JMAJ 47(6): 259 264, 2004 Jun NAKAMURA Professor, Department of Psychiatry, School of Medicine, University of Occupational and Environmental
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationCONTRAINDICATIONS TABLE
CONTRAINDICATIONS TABLE Generic Name Brand Name Contraindications Amphetamine Salts Adderall, Adderall XR Hypersensitivity to amphetamine, dextroamphetamine, or other sympathomimetic amines Advanced arteriosclerosis
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationGUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS
City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE
More informationAntidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder
updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants
More informationPhenothiazine Derivatives in Urine: False Negative Results With the Forrest Color Test (FPN), and a Method for Their Elimination
Phenothiazine Derivatives in Urine: False Negative Results With the Forrest Color Test (FPN), and a Method for Their Elimination K. N. Campbell More than 100 Forrest color tests (FPN) were performed on
More informationPolicy Evaluation: Low Dose Quetiapine Safety Edit
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503
More informationTherapeutic drug monitoring. Department of Clinical Pharmacology, Wrocław Medical University
Therapeutic drug monitoring Department of Clinical Pharmacology, Wrocław Medical University Therapeutic index concentration range characterized by a high efficacy of action and low risk of upper toxic
More informationAdverse events of common psychiatric medications: an umbrella review
Adverse events of common psychiatric medications: an umbrella review Katrina Bartellas, 1 Thomas Bajorek 1 Sarah Stockton, 1 Stefan Leucht, 2 Andrea Cipriani, 1 Seena Fazel 1 1 Department of Psychiatry,
More informationM E D I C A T I O N S & Sean M. Jeffery
M E D I C A T I O N S & Sean M. Jeffery Subtitle Could my medications be causing me to fall? A discussion on medication safety and falls prevention. Contact Information & Disclosure Sean M. Jeffery, PharmD,
More information11. Psychopharmacological Intervention
11. Psychopharmacological Intervention 11.1 Goals of Psychopharmacology The goal of psychopharmacology is to ensure that patients with more severe forms of depression and those who fail to benefit adequately
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve 50 mg/ml solution for injection for dogs (AT, BE, BG, CY, CZ, DE, EL, ES, HR, HU, IE, IT, LU, NL, PT, RO,
More informationAnti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of.
30-3-2007 Anti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of. 30-3-2018 C. Psychiatric drugs: controlled trial demonstrated
More information